報價延遲最少15分鐘:2025/02/23 04:13 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.77 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.35/-3.32
|
|
企業價值
60.94M
|
| 資產負債 |
|
每股賬面淨值
-4.09
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
70.99M
|
|
每股收益
7.18
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/23 04:13 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasonepropionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. |